Pfizer Income After Taxes 2010-2024 | PFE
Pfizer annual/quarterly income after taxes history and growth rate from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
- Pfizer income after taxes for the quarter ending September 30, 2024 was $4.481B, a 287.65% decline year-over-year.
- Pfizer income after taxes for the twelve months ending September 30, 2024 was $4.306B, a 59.02% decline year-over-year.
- Pfizer annual income after taxes for 2023 was $2.173B, a 93.08% decline from 2022.
- Pfizer annual income after taxes for 2022 was $31.401B, a 39.81% increase from 2021.
- Pfizer annual income after taxes for 2021 was $22.459B, a 236.92% increase from 2020.
Pfizer Annual Income After Taxes
(Millions of US $) |
| 2023 |
$2,173 |
| 2022 |
$31,401 |
| 2021 |
$22,459 |
| 2020 |
$6,666 |
| 2019 |
$10,738 |
| 2018 |
$3,860 |
| 2017 |
$21,354 |
| 2016 |
$7,228 |
| 2015 |
$6,975 |
| 2014 |
$9,120 |
| 2013 |
$11,410 |
| 2012 |
$9,021 |
| 2011 |
$7,860 |
| 2010 |
$8,318 |
| 2009 |
$8,529 |
Pfizer Quarterly Income After Taxes
(Millions of US $) |
| 2024-09-30 |
$4,481 |
| 2024-06-30 |
$31 |
| 2024-03-31 |
$3,128 |
| 2023-12-31 |
$-3,334 |
| 2023-09-30 |
$-2,388 |
| 2023-06-30 |
$2,340 |
| 2023-03-31 |
$5,555 |
| 2022-12-31 |
$5,001 |
| 2022-09-30 |
$8,645 |
| 2022-06-30 |
$9,877 |
| 2022-03-31 |
$7,878 |
| 2021-12-31 |
$3,578 |
| 2021-09-30 |
$8,171 |
| 2021-06-30 |
$5,826 |
| 2021-03-31 |
$4,884 |
| 2020-12-31 |
$662 |
| 2020-09-30 |
$917 |
| 2020-06-30 |
$2,604 |
| 2020-03-31 |
$2,483 |
| 2019-12-31 |
$-5,888 |
| 2019-09-30 |
$7,680 |
| 2019-06-30 |
$5,056 |
| 2019-03-31 |
$3,890 |
| 2018-12-31 |
$-7,701 |
| 2018-09-30 |
$4,111 |
| 2018-06-30 |
$3,879 |
| 2018-03-31 |
$3,571 |
| 2017-12-31 |
$12,290 |
| 2017-09-30 |
$2,858 |
| 2017-06-30 |
$3,076 |
| 2017-03-31 |
$3,130 |
| 2016-12-31 |
$762 |
| 2016-09-30 |
$1,355 |
| 2016-06-30 |
$2,063 |
| 2016-03-31 |
$3,048 |
| 2015-12-31 |
$-165 |
| 2015-09-30 |
$2,130 |
| 2015-06-30 |
$2,634 |
| 2015-03-31 |
$2,376 |
| 2014-12-31 |
$1,258 |
| 2014-09-30 |
$2,676 |
| 2014-06-30 |
$2,921 |
| 2014-03-31 |
$2,265 |
| 2013-12-31 |
$2,631 |
| 2013-09-30 |
$2,588 |
| 2013-06-30 |
$3,575 |
| 2013-03-31 |
$2,616 |
| 2012-12-31 |
$1,308 |
| 2012-09-30 |
$2,989 |
| 2012-06-30 |
$3,000 |
| 2012-03-31 |
$1,724 |
| 2011-12-31 |
$790 |
| 2011-09-30 |
$2,325 |
| 2011-06-30 |
$2,521 |
| 2011-03-31 |
$2,224 |
| 2010-12-31 |
$2,994 |
| 2010-09-30 |
$856 |
| 2010-06-30 |
$2,454 |
| 2010-03-31 |
$2,014 |
| 2009-12-31 |
$658 |
| 2009-09-30 |
$2,879 |
| 2009-06-30 |
$2,263 |
| 2009-03-31 |
$2,729 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
